Android app on Google Play

Streetinsider.com Pre-Open Movers 07/11: (RMTI) (BPI) (ALNY) Higher; (LEDS) (MACK) (PSMT) Lower (more...)

July 11, 2013 9:30 AM EDT Send to a Friend
Get Alerts RMTI Hot Sheet
Trade RMTI Now!
Join SI Premium – FREE
Rockwell Medical (NASDAQ: RMTI) 27.7% HIGHER; announced successful top-line results from the long-term CRUISE-1 Phase 3 efficacy study of SFP. SFP is the Company's late-stage investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. In the Phase 3 efficacy study, SFP met the primary endpoint, demonstrating a statistically significant mean change in hemoglobin from baseline to End-of-Treatment. Additionally, SFP met key secondary endpoints, including maintenance of hemoglobin, maintenance of reticulocyte hemoglobin, and increase in serum iron pre-to-post treatment without an increase in ferritin. This long-term study is the first of two identical Phase 3 efficacy studies to provide clinical data required for the Company to file a New Drug Application (NDA) with the U.S. FDA.

Bridgepoint Education, Inc. (NYSE: BPI) 25.3% HIGHER; Ashford University, has been granted initial accreditation for five years by the Accrediting Commission for Senior Colleges and Universities of the Western Association of Schools and Colleges (WASC). The WASC Commission Action Letter stated "The Commission found that the University has responded to Commission concerns and judges that it is now in substantial compliance with Commission standards."

SemiLEDs Corp. (NASDAQ: LEDS) 16% LOWER; reported Q3 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $5.17 million. GAAP gross margin for the third quarter of fiscal 2013 was negative 129%, compared with gross margin for the third quarter of fiscal 2012 of negative 11%. Operating margin for the third quarter of fiscal 2013 was negative 278% compared with negative 87% in the third quarter of fiscal 2012.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) 13.4% HIGHER; announced positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The company is reporting that ALN-TTRsc achieved robust and statistically significant (p<0.01) knockdown of serum TTR protein levels of greater than 80% in healthy volunteer subjects, in line with results for ALN-TTRsc previously reported in non-human primates. In addition, to date ALN-TTRsc was found to be generally safe and well tolerated. Dose escalation in this trial continues and results will be presented at the Annual Scientific Meeting of the Heart Failure Society of America (HFSA), being held September 22 – 25, 2013 in Orlando, Fla. These human study results are the first to be reported for Alnylam’s proprietary GalNAc-siRNA conjugate delivery platform, enabling subcutaneous dosing of RNAi therapeutics with a wide therapeutic index.

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) 10.4% LOWER; announced its intention to offer, subject to market and other conditions, $50 million of its common stock and $75 million in aggregate principal amount of its convertible senior notes due 2020 (the "Notes") in concurrent underwritten public offerings pursuant to Merrimack's effective Registration Statement on Form S-3 (File No. 333-186369).

GTX Inc. (NASDAQ: GTXI) 9.2% HIGHER; Defended at Wedbush after big drop on Wednesday.

Sunshine Heart (NASDAQ: SSH) 7% HIGHER; Oppenheimer initiates coverage with a Outperform. PT $11.00.

Apollo Group Inc. (NASDAQ: APOL) 7% HIGHER; on July 9, 2013, University of Phoenix, Inc., its whollyowned subsidiary, was notified by The Higher Learning Commission (HLC) that its accreditation was reaffirmed through the 20222023 academic year, and that the University was placed on Notice status. HLC, a commission member of the North Central Association of Colleges and Schools, is the regional accreditor of the University.

Pricesmart, Inc. (NASDAQ: PSMT) 5.1% LOWER; reported Q3 EPS of $0.61, $0.03 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $571.7 million versus the consensus estimate of $573.56 million.

AMD (NYSE: AMD) 3.8% HIGHER; upgraded to Buy at Canaccord and BofA/ML.

VOXX International (NASDAQ: VOXX) 3.8% HIGHER; reported Q1 EPS of $0.09, $0.05 better than the analyst estimate of $0.04. Revenue for the quarter came in at $193 million versus the consensus estimate of $191.97 million

KB Home (NYSE: KBH) 3.6% HIGHER; upgraded to Buy at CRT

Finisar Corp. (NASDAQ: FNSR) 3.2% HIGHER; Upgraded to Strong Buy at Needham & Company

Zumiez Inc. (NASDAQ: ZUMZ) 3.1% LOWER; announced that total net sales for the five-week period ended July 6, 2013 increased 14.5% to $58.8 million, compared to $51.3 million for the five-week period ended June 30, 2012. The Company's comparable store sales increased 1.0% for the five-week period ended July 6, 2013 compared to a comparable store sales increase of 8.2% for the five-week period ended June 30, 2012.

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) 1.6% LOWER; entered into definitive agreements with investors to purchase an aggregate of 657,144 shares of common stock at a price of $7.00 per share in a registered direct offering. The offering is expected to close on or about July 16, 2013, subject to the satisfaction of customary closing conditions.

Penn National Gaming, Inc. (PENN: Nasdaq) 1% HIGHER; announced today that the Nevada Gaming Control Board unanimously approved the steps necessary to implement the previously announced planned separation of its operating assets and real property assets. In order to complete the regulatory process in Nevada, the Company must now obtain the approval of the Nevada Gaming Commission, which is scheduled to consider the matter on July 25, 2013.

Yum! Brands, Inc. (NYSE: YUM) 0.6% HIGHER; reported Q2 EPS of $0.56, versus the analyst estimate of $0.54. Revenue for the quarter came in at $2.9 billion versus the consensus estimate of $2.93 billion.




You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Needham & Company, Bank of America, S3

Add Your Comment